
Pharmacally
ERLEADA
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in ERLEADA
Clinical TrialsJ&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADTJohnson & Johnson reports that perioperative ERLEADA (apalutamide) plus androgen deprivation therapy reduced the hazard of event-free survival events by 62% versus surgery alone in high-risk localized or…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.